ライフサイエンスコーパス: Zeiss

1 two hydrophilic IOL models (CT Spheris 204, Zeiss; Lentis L-313, Oculentis) and one hydrophobic cont

2 planted with diffractive IOL Acri.Lisa 366D (Zeiss, Oberkochen, Germany).

3 ered 6 x 6-mm OCT scans (CIRRUS HD-OCT 5000; Zeiss).

4 t preop measurements with the IOLMaster 700 (Zeiss, Jena, Germany) and surgery with the LenSx device

5 Topcon-TRK-2P) and AL with an IOLMaster-700 (Zeiss) at 6-month intervals.

6 h the Humphrey Field Analyzer III (model 850 Zeiss) using the SS and SFR strategies.

7 A Zeiss-Humphrey/Welch Allyn FDT perimeter was used with t

8 ra; Versacam & Trade & Alpha, France), and a Zeiss portable fundus camera (Zeiss Visucout 100).

9 We have implemented this assay method into a Zeiss uHTS system and screened compound libraries for he

10 Serial OCTA using a Zeiss Plex Elite 9000 was used to evaluate reperfusion p

11 tomography angiography was performed using a Zeiss PLEX Elite instrument with a 6 x 6-mm scan pattern

12 the cross-sectional histologic images was a Zeiss Axioskop 40 microscope with an objective lens Zeis

13 re assessed on UWF-CF images acquired with a Zeiss Clarus 700.

14 re performed in an office-based suite with a Zeiss surgical microscope by two board-certified ophthal

15 -mm macular scans were captured using OCT-A (Zeiss AngioPlex, software version 11.0; Cirrus HD-OCT 50

16 ation, axial length (Zeiss IOLMaster 500 and Zeiss IOLMaster 700), presence of pseudoexfoliation mate

17 rred Optos P200DTx for 28 sessions (58%) and Zeiss Clarus 500 for 20 (42%; P = 0.15).

18 aged with Optos P200DTx, single-capture, and Zeiss Clarus 500, 2 capture montages when possible, UWF

19 x captured unique findings in 28 images, and Zeiss Clarus 500 captured unique findings 1 image (P < 0

20 nt SD-OCT devices (Heidelberg Spectralis and Zeiss Cirrus) at 2 clinical sites were used to train and

21 , the custom algorithm's RNFL thickness, and Zeiss' RNFL thickness was 0.980, 0.929, and 0.946, respe

22 rs (Zeiss Cirrus HD-OCT 5000 with AngioPlex; Zeiss Meditec).

23 ess measures from the commercially available Zeiss SD-OCT machine were obtained.

24 Between Zeiss' RNFL and the custom algorithm's RNFL, and the stu

25 Moreover, GANSeg generalized to both Zeiss and Topcon Maestro2 swept-source OCT domains, whic

26 France), and a Zeiss portable fundus camera (Zeiss Visucout 100).

27 timate of visual field loss; P = 0.003; Carl Zeiss Meditec, Inc., Dublin, CA).

28 as of the Humphrey Field Analyzer 24-2 (Carl Zeiss Meditec, Inc., Dublin, CA) visual field and the ax

29 red using the modified MPD-Visucam 200 (Carl Zeiss Meditec) and the modified Heidelberg Retina Angiog

30 eld (VF) testing (SITA - Standard 24-2; Carl Zeiss Meditec, Dublin, CA) and EDI OCT imaging (Spectral

31 tatic perimetric fields (Humphrey 30-2; Carl Zeiss Meditec, Dublin, CA) were obtained annually for 4

32 0x200 scan using the Cirrus SD OCT 400 (Carl Zeiss Meditec, Inc., Dublin, CA) was carried out first w

33 opters measured with the IOLMaster 500 (Carl Zeiss Meditec AG) were included.

34 ry was obtained with the IOLMaster 500 (Carl Zeiss Meditec AG, Jena, Germany) and Pentacam (OCULUS In

35 preoperatively using the IOLMaster 500 (Carl Zeiss Meditec, Dublin, CA) to calculate the Haigis-L and

36 Spectral-domain CIRRUS 5000 (Carl Zeiss Meditec, Dublin, CA) OCTA images with no macular e

37 tware version 11.0; Cirrus HD-OCT 5000, Carl Zeiss Meditec Inc).

38 either 360 degrees ALPI (Visulas 532s; Carl Zeiss Meditec, Jena, Germany) or medical therapy (Travop

39 ptical biometry with the IOLMaster 700 (Carl Zeiss Meditec AG) was performed preoperatively.

40 using either the IOLMaster 500 or 700 (Carl Zeiss Meditec AG, Jena, Germany).

41 ments were obtained from IOLMaster 700 (Carl Zeiss Meditec).

42 iSD-OCT) assisted PPV using Rescan 700 (Carl Zeiss Meditech, Jena, Germany) with epiretinal membrane

43 mography-based biometry (IOLMaster 700; Carl Zeiss Meditec AG).

44 ments included biometry (IOLMaster 700; Carl Zeiss Meditec).

45 ndard program 24-2; Humphrey model 750 [Carl Zeiss Meditec, Dublin, CA]) printouts.

46 ral field (Humphrey Field Analyzer 750; Carl Zeiss Meditec).

47 o., Ltd., China] and the AT LARA 829MP [Carl Zeiss Meditec, Germany].

48 , Liege, Belgium) or AT Lisa tri 839MP (Carl Zeiss AG, Jena, Germany).

49 cal diffractive IOL (AT LISA tri 839MP, Carl Zeiss Meditech, Germany).

50 th the SS-OCTA system (PLEX Elite 9000, Carl Zeiss Meditec Inc., Dublin, CA, USA).

51 ith the SS-OCT system (PLEX Elite 9000, Carl Zeiss Meditec Inc., Dublin, CA, USA).

52 cking: 9) and SS-OCTA (PLEX Elite 9000, Carl Zeiss Meditec, 500x500 angio pattern) instruments.

53 Hz SS-OCTA instrument (PLEX Elite 9000, Carl Zeiss Meditec, Dublin, CA) using a 6x6-mm field of view

54 ) and SS-OCTA imaging (PLEX Elite 9000, Carl Zeiss Meditec, Dublin, CA) were performed at the same da

55 Hz SS-OCTA instrument (PLEX Elite 9000, Carl Zeiss Meditec, Dublin, California, USA).

56 e imaged using SS OCT (PLEX Elite 9000; Carl Zeiss Meditec, Dublin, CA), with follow-up imaging perfo

57 e imaged with SS-OCTA (PLEX Elite 9000; Carl Zeiss Meditec, Dublin, California, USA) using both 3x3-m

58 x 12-mm field of view (PLEX Elite 9000; Carl Zeiss Meditec, Inc, Dublin, CA) at baseline and at 1 wee

59 A2, Carl Zeiss Meditec Inc., Dublin, CA) was investigated.

60 ression by Guided Progression Analysis (Carl Zeiss Meditec) of serial RNFL thickness maps.

61 (Cirrus HD-OCT RPE Elevation Analysis; Carl Zeiss Meditec).

62 ith the Humphrey Visual Field Analyzer (Carl Zeiss Meditec, Dublin, CA) from 189 normal eyes and 156

63 program of the Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) of 76 patients with open-angl

64 rd, 24-2 test, Humphrey Field Analyzer, Carl Zeiss Meditec, Dublin, CA) and confocal scanning laser t

65 after injury) (Humphrey Field Analyzer, Carl Zeiss Meditec, Dublin, CA, Swedish Interactive Threshold

66 A-fast (Humphrey Visual Field Analyzer, Carl Zeiss Meditec, Inc, Dublin, CA) demonstrated diffuse dep

67 over 3 months (Humphrey Field Analyzer, Carl Zeiss Meditec; SITA Standard, 24-2).

68 spot size III; Humphrey Field Analyzer; Carl Zeiss Meditec, Inc., Dublin, CA) and frequency domain op

69 al field test (Humphrey Field Analyzer; Carl Zeiss Meditec, Inc., Dublin, CA).

70 ing the Zeiss Cirrus HD-5000 AngioPlex (Carl Zeiss AG).

71 ng Zeiss Cirrus HD-5000 with AngioPlex (Carl Zeiss Meditec, Dublin, CA) and underwent cognitive evalu

72 ing the Zeiss Cirrus HD-5000 AngioPlex (Carl Zeiss Meditec, Dublin, CA) and volumetric brain MRI imag

73 OCTA CIRRUS 5000 HD-OCT with AngioPlex (Carl Zeiss Meditec, Dublin, CA, USA).

74 A software (Cirrus 5000 with AngioPlex; Carl Zeiss Meditec).

75 cipants underwent gonioscopy and ASOCT (Carl Zeiss Meditec, Dublin, CA).

76 nt optical coherence tomography (ASOCT, Carl Zeiss Meditec, Dublin, CA).

77 ometry (the IOLMaster optical biometer; Carl Zeiss Meditec).

78 on, Laboratories) [System 4], Bluesert (Carl Zeiss Meditec) [System 5], and Prosert (OphthalmoPro Gmb

79 corneal compensation (GDx VCC; both by Carl Zeiss Meditec, Dublin, CA), according to different level

80 coherence tomography; both produced by Carl Zeiss Meditec, Inc., Dublin, CA), and optic nerve head (

81 and healthy subjects using the Cirrus (Carl Zeiss Meditec Inc., Dublin, CA) and Spectralis (Heidelbe

82 eidelberg Engineering GmbH) and Cirrus (Carl Zeiss Meditec) OCT scans were taken within one year from

83 O, n = 400) acquired with Zeiss Cirrus (Carl Zeiss Meditec, Dublin, CA) (n = 600) or Heidelberg Spect

84 RNFL) thickness, as measured by Cirrus (Carl Zeiss, Oberkochen, Germany) optic coherence tomography (

85 HD-OCT (Cirrus; Carl Zeiss Meditec, Dublin, CA) volume scans (512 x 128) were

86 Prototype SD-OCTA devices (Cirrus; Carl Zeiss Meditec, Inc, Dublin, California, USA) were used t

87 n fundus autofluorescence (GAF; Clarus, Carl Zeiss Meditec), blue fundus autofluorescence (BAF; Spect

88 color fundus photography (CFP; Clarus, Carl Zeiss Meditec), near-infrared imaging (NIR; Spectralis,

89 s: scanning laser polarimetry (GDx ECC; Carl Zeiss Meditec, Dublin, CA), confocal scanning laser opht

90 Humphrey Matrix FDT (Carl Zeiss Meditec, Inc, Dublin, CA) testing was performed wi

91 , consisting of Humphrey visual fields (Carl Zeiss Meditech), macular integrity assessment perimetry,

92 mpensation; Glaucoma Diagnostics (GDx), Carl Zeiss Meditec, Dublin, CA) nerve fiber indicator (NFI),

93 hods: Guided Progression Analysis (GPA; Carl Zeiss Meditec, Inc) and a United States Food and Drug Ad

94 using the Humphrey Field Analyzer (HFA; Carl Zeiss Meditec, Dublin, CA) SITA Fast 24-2 protocol.

95 s using a Humphrey Field Analyzer (HFA; Carl Zeiss Meditec, Dublin, CA; 24-2 Swedish interactive thre

96 lity of the Humphrey visual field (HVF; Carl Zeiss Meditec, Dublin, CA) test in subjects with glaucom

97 y maps from Humphrey visual field (HVF; Carl Zeiss Meditec, Inc., Dublin, CA) testing, as well as FDO

98 y testing (Humphrey Visual Field [HVF]; Carl Zeiss Meditec, Dublin, CA) and scanning laser ophthalmos

99 ent using a Humphrey Field Analyzer II (Carl Zeiss Meditec, Inc., Dublin, CA).

100 ted into a commercial OCT unit (OCT II; Carl Zeiss Meditec, Inc., Dublin, CA) and tested on healthy s

101 aminations (Humphrey Field Analyzer II; Carl Zeiss Meditec, Inc., Dublin, CA) in visual field series

102 s spectral-domain OCT (SD-OCT) imaging (Carl Zeiss Meditec, Dublin, CA) using the optic disc and macu

103 totype Zeiss 100 kHz SS-OCT instrument (Carl Zeiss Meditec Inc, Dublin, CA).

104 r depth was determined using IOLMaster (Carl Zeiss Meditec).

105 and 30 myopes, by using the IOLMaster (Carl Zeiss Meditec, Inc., Dublin, CA), while accommodative st

106 vature were measured with an IOLMaster (Carl Zeiss Meditec, Welwyn Garden City, U.K.) at age 15 years

107 ACD) were measured using the IOLMaster (Carl Zeiss Meditech AG, Jena, Germany).

108 rence interferometry device (IOLMaster; Carl Zeiss Meditec, Inc., Dublin, CA) and an immersion ultras

109 g a Cirrus high definition OCT machine (Carl Zeiss Meditec) at Sankara Nethralaya Eye Hospital, Chenn

110 The Humphrey Matrix (Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY)

111 derwent imaging with the Cirrus HD-OCT (Carl Zeiss Meditec Inc) using a macular cube protocol of 512

112 19 studies, 3094 subjects), Cirrus OCT (Carl Zeiss Meditec Inc., Dublin, CA) (14 studies, 2164 subjec

113 eyes were imaged by the Cirrus HD-OCT (Carl Zeiss Meditec Inc., Dublin, CA) and had visual field tes

114 l fluid was identified on standard OCT (Carl Zeiss Meditec) an additional macular OCT (Spectralis Hei

115 n was examined by anterior segment OCT (Carl Zeiss Meditec) and the scans were analyzed in 2 axes (18

116 ans obtained using spectral-domain OCT (Carl Zeiss Meditec) between 1 and 2 months after surgery were

117 The deviation map from the Cirrus OCT (Carl Zeiss Meditec) Ganglion Cell Analysis (GCA) was extracte

118 s underwent Cirrus spectral-domain OCT (Carl Zeiss Meditec) imaging of the optic disc and macular cub

119 ts of RNFL thickness on the Cirrus OCT (Carl Zeiss Meditec) with signal strength of 6 or more.

120 ne (ERM) by Cirrus spectral-domain OCT (Carl Zeiss Meditec) within a 2-year period.

121 Heidelberg, Germany) and Cirrus SD-OCT (Carl Zeiss Meditec, Dublin, CA) imaging over 36 months at 6-m

122 cular scanning using the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA) macula 200x200 acquisition pr

123 kness was measured using Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA).

124 s with Cirrus high-definition (HD)-OCT (Carl Zeiss Meditec, Dublin, CA).

125 morphology was assessed by Stratus OCT (Carl Zeiss Meditec, Dublin, CA).

126 ipants underwent gonioscopy and AS-OCT (Carl Zeiss Meditec, Dublin, CA).

127 eyes were imaged by the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA; optic nerve head and macular

128 obtained annually with the Stratus OCT (Carl Zeiss Meditec, Inc., Dublin, CA) along with optic disc s

129 dB) were imaged with OCT (Stratus OCT, Carl Zeiss Meditec, Inc., Dublin, CA) and tested with SAP (Hu

130 ical coherence tomography (Visante OCT, Carl Zeiss Meditec, Jena, Germany).

131 im, Germany) and SD-OCT (Cirrus HD-OCT; Carl Zeiss Meditec AG, Dublin, CA) at approximately 4-month i

132 al coherence tomography (Cirrus HD-OCT; Carl Zeiss Meditec Inc, Dublin, CA).

133 bed Cirrus high-definition OCT (HD-OCT; Carl Zeiss Meditec) methods that offer clinical advantages fo

134 t AS optical coherence tomography (OCT; Carl Zeiss Meditec, Dublin, CA).

135 esponding SD OCT images (Cirrus HD-OCT; Carl Zeiss Meditec, Dublin, California, USA) were included.

136 ermany), AngioPlex (Cirrus 5000 HD-OCT; Carl Zeiss Meditec, Inc, Dublin, California, USA), prototype

137 tical coherence tomography (Cirrus OCT; Carl Zeiss Meditec, Inc, Dublin, California, USA).

138 atus optical coherence tomography (OCT; Carl Zeiss Meditec, Inc., Dublin, CA) images were analyzed wi

139 512 x 128 scan protocol; Cirrus HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA) was obtained from healt

140 ectance, spectral-domain OCT, and OCTA (Carl Zeiss Meditec), were performed.

141 Fremont, CA) and Cirrus/AngioPlex OCTA (Carl Zeiss Meditec, Inc, Dublin, CA) systems.

142 California, USA), prototype PlexElite (Carl Zeiss Meditec), RS-3000 Advance (Nidek, Gamagori, Japan)

143 performed using a PlexElite prototype (Carl Zeiss Meditec, Inc.).

144 Progression Analysis software for SAP (Carl Zeiss Meditec, Inc.) and by masked assessment of optic d

145 FDT 24-2 Humphrey Matrix and SAP SITA (Carl Zeiss Meditec, Inc., Dublin, CA).

146 teractive Thresholding Algorithm, SITA; Carl Zeiss Meditec, Inc.) within 3 months of each other.

147 rrus 5000 with Angioplex OCTA software (Carl Zeiss Meditec, Dublin, CA).

148 SAP visual fields (SITA-standard; Carl Zeiss Meditec, Inc., Dublin, CA) were obtained within 22

149 area under the curve (AUC) and STATPAC (Carl Zeiss Meditec, Inc., Dublin, CA) PSD were compared.

150 optical coherence tomography (Stratus, Carl Zeiss Meditech AG).

151 StratusOCT (Carl Zeiss Meditec, Inc., Dublin, CA) images were collected f

152 The raw exported StratusOCT (Carl Zeiss Meditec, Inc., Dublin, CA) scan data from 20 eyes

153 coherence tomography (OCT; StratusOCT; Carl Zeiss Meditec, Dublin, CA) and scanning laser ophthalmos

154 tical coherence tomography (StratusOCT; Carl Zeiss Meditec, Inc.).

155 , using the Zeiss VisuMax Laser system (Carl Zeiss Meditec AG, Jena, Germany) at Oculens Clinic, Cluj

156 using VisuMax(R) 500 kHz laser system (Carl Zeiss Meditec, Jena, Germany) and the second group inclu

157 24-2 Humphrey visual field (HVF) test (Carl Zeiss Meditec, Dublin, CA); and (2) glaucomatous damage

158 Siegfried Czapski, the developer of the Carl Zeiss corneal biomicroscope, the direct precursor of tod

159 AT LISA trifocal IOL (AT LISA tri839MP; Carl Zeiss Meditec, Jena, Germany) pre-enrollment.

160 canning laser polarimeter (the GDx VCC; Carl Zeiss Meditec, Inc., Dublin, CA) assessed by receiver op

161 able Corneal and Lens Compensator (VCC; Carl Zeiss Meditec, Inc., Dublin, CA), the Heidelberg Retina

162 nd scanning laser polarimetry (GDx-VCC; Carl Zeiss Meditec, Inc., Dublin, CA).

163 by scanning laser polarimetry (GDx VCC; Carl Zeiss Meditec, Inc., Dublin, CA).

164 with 5 or more prior Humphrey 24-2 VFs (Carl Zeiss Meditec, Inc, Dublin, CA).

165 We analyzed ASOCT images (Visante, Carl Zeiss Meditec, Dublin, CA) from all subjects using custo

166 m anterior segment OCT images (Visante; Carl Zeiss Meditec, Inc., Dublin, CA) at 1 (CBT1), 2 (CBT2) a

167 treated in each eye using the VisuMax (Carl Zeiss Meditec, Jena, Germany) 500-kHz femtosecond laser

168 cheimpflug and ocular wavefront (WASCA, Carl Zeiss Meditec AG) measurements were performed at the 3-m

169 D imaged with SS-OCTA (PLEX Elite 9000, Carl-Zeiss Meditec Inc) at the University of Iowa from Septem

170 g SS-OCT with SS-OCTA (PLEX Elite 9000; Carl-Zeiss Meditec Inc., Dublin, CA).

171 g the Guided Progression Analysis (GPA; Carl-Zeiss Meditec, Inc., Dublin, CA).

172 any), and the Stratus OCT (Stratus OCT; Carl-Zeiss Meditec, Inc.) within a 6-month period.

173 only on patients evaluated with the Cirrus (Zeiss) platform (n = 28).

174 d Kingdom]) and spectral-domain OCT (Cirrus; Zeiss, Oberkochen, Germany) scans were obtained and anal

175 mages were obtained with the spectral domain Zeiss OCT5000.

176 laucoma patients (60 undergoing SITA-Faster [Zeiss Meditec] testing on 24-2 and 24-2C; 40 undergoing

177 inutes (standard deviation, 3.0 minutes) for Zeiss Clarus 500 (P = 0.17).

178 graders also manually segmented 3 OCTs from Zeiss Plex Elite 9000 and Topcon Maestro2.

179 sis software (Atlas 9000 with Pathfinder II, Zeiss Meditec), tomography (Pentacam, Oculus), dual Sche

180 delberg Spectralis system) and OCTA imaging (Zeiss PlexElite 9000) were obtained.

181 image capture and cross-linking functions in Zeiss Zen Black with image processing in FIJI.

182 avidin-biotin and Cuprolinic Blue labeling, Zeiss M2 Imager, and Neurolucida to characterize spinal

183 ata on preexisting medication, axial length (Zeiss IOLMaster 500 and Zeiss IOLMaster 700), presence o

184 xioskop 40 microscope with an objective lens Zeiss A-Plan x 20/0.45 (Zoom 6.3 x TV 2/3""C).

185 actometry (Topcon), Pentacam HR, IOL Master (Zeiss) axial length measurements and fundus optical cohe

186 om Cirrus (200 x 200 macular cube, 6 x 6 mm; Zeiss Meditec, CA) and Spectralis (20 degrees x 20 degre

187 e subset of 52 of 70 registered and montaged Zeiss Clarus 500 images, similar results were found.

188 images obtained with SD-OCT (Cirrus HD-OCT, Zeiss Meditec, Dublin, California, USA) with 5.1.1 anter

189 Images were captured on Bioptigen SD-OCT, Zeiss Cirrus HD-OCT, and Heidelberg Spectralis in 42 eye

190 ction in the CALLISTO eye group was based on Zeiss VERACITY Surgery Planner (a web-based tool) and on

191 to utilization of ultrasound biometry and/or Zeiss IOLMaster, axial length corrections with our mean

192 24 preferred Optos P200DTx and 20 preferred Zeiss Clarus 500 (P = 0.52).

193 imaging, as well as imaging with a prototype Zeiss 100 kHz SS-OCT instrument (Carl Zeiss Meditec Inc,

194 24-2 and 24-2C; 40 undergoing SITA-Standard [Zeiss Meditec] testing on 24-2 and SITA-Faster on 24-2C)

195 Medtronic, Cook Medical, Rymed, Karl-Storz, Zeiss, and Olympus.

196 groups imaged with the Cirrus HD-OCT system (Zeiss, Oberkochen, Germany) were included.

197 n a Humphrey Field Analyzer (HFA) 24-2 test (Zeiss Humphrey Systems, Dublin, CA), and on a custom fre

198 omated Humphrey perimetry (SITA 24-2) tests (Zeiss, Dublin, CA), using OCT scans centered on MAC, ONH

199 ore and MD were obtained from 24-2 VF tests (Zeiss-Humphrey Systems, Dublin, CA) at two visits approx

200 least 5 measurements over follow-up from the Zeiss Cirrus OCT or Humphrey Field Analyzer.

201 apillaris slab flow images obtained from the Zeiss Plex Elite 9000.

202 ssed with the ultrasound biometry and/or the Zeiss IOLMaster.

203 onditions, by using the information that the Zeiss i.Profiler(plus) gathers of ocular aberrations (lo

204 ere acquired from all participants using the Zeiss Cirrus 5000 with Angioplex OCTA software (Carl Zei

205 ent OCT angiography (OCTA) imaging using the Zeiss Cirrus HD-5000 AngioPlex (Carl Zeiss AG).

206 and OCT angiography (OCTA) imaging using the Zeiss Cirrus HD-5000 AngioPlex (Carl Zeiss Meditec, Dubl

207 S (SD: +/-15.2 years, range 18-65) using the Zeiss Visante AS-OCT and Medmont M300 corneal topographe

208 o underwent ReLEX SMILE technique, using the Zeiss VisuMax Laser system (Carl Zeiss Meditec AG, Jena,

209 ween August 2018 and December 2019 using the Zeiss Visuscout 100 handheld camera.

210 al area in all 4 quadrants compared with the Zeiss Clarus 500.

211 tions of the subjects were recorded with the Zeiss i.Profiler(plus).

212 obtained with the software packaged with the Zeiss laser-scanning microscope (LSM AIM, version 3.2).

213 This Zeiss invention lacked only the slit illumination of tod

214 nts and fundus optical coherence tomography (Zeiss).

215 All the specimens were examined under Zeiss confocal laser scanning microscopy.

216 Images were digitized using Zeiss Axiovision software and densitometrically analyzed

217 s measured around the optic nerve head using Zeiss Stratus optical coherence tomography and related t

218 Participants were imaged using Zeiss Cirrus HD-5000 with AngioPlex (Carl Zeiss Meditec,

219 pth imaging foveal scans were obtained using Zeiss Cirrus HD-5000 AngioPlex.

220 address a range of research questions using Zeiss Zen Black microscopy systems and LC-MS protocols t

221 Using 55 eyes with valid Zeiss RNFL measurements, Pearson's correlation coefficie

222 orm for cataract surgery planning (Veracity, Zeiss Meditec).

223 ptical coherence tomography (AS-OCT Visante, Zeiss Meditec AG) and optical tomography (Pentacam, OCUL

224 vein occlusion (RVO, n = 400) acquired with Zeiss Cirrus (Carl Zeiss Meditec, Dublin, CA) (n = 600)

225 captured more relative pixels compared with Zeiss Clarus 500: 510.4 versus 355.6 (P < 0.001) in tota

226 Retinal area was measured with Zeiss Clarus 500 images that were registered to the Opto

227 CTA) were performed at baseline and 2 years (Zeiss Cirrus HD-OCT 5000 with AngioPlex; Zeiss Meditec).